PT  - JOURNAL ARTICLE
AU  - Farrera-Soler, Lluc
AU  - Daguer, Jean-Pierre
AU  - Barluenga, Sofia
AU  - Cohen, Patrick
AU  - Pagano, Sabrina
AU  - Yerly, Sabine
AU  - Kaiser, Laurent
AU  - Vuilleumier, Nicolas
AU  - Winssinger, Nicolas
TI  - Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma
AID  - 10.1101/2020.06.15.20131391
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.15.20131391
4099  - http://medrxiv.org/content/early/2020/06/19/2020.06.15.20131391.short
4100  - http://medrxiv.org/content/early/2020/06/19/2020.06.15.20131391.full
AB  - A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) is the source of a current pandemic (COVID-19) with devastating consequences in public health and economic stability. Using a peptide array to map the antibody response of plasma from healing patients, we identified immunodominant linear epitopes corresponding to key proteolytic sites on the spike protein.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge funding from the University of Geneva and the departement d instruction public du canton de Geneve.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Anonymized leftovers of whole blood-EDTA were used for this method evaluation, in accordance with the ethical committee of our institution and national regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analytical data is included in the supplementary information file.